Carmel B Nanthakumar
Overview
Explore the profile of Carmel B Nanthakumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan M, Poeckel D, Halavatyi A, Zukowska-Kasprzyk J, Stein F, Vappiani J, et al.
Eur Respir J
. 2020 Dec;
58(1).
PMID: 33361096
Fibrosis can affect any organ, resulting in the loss of tissue architecture and function with often life-threatening consequences. Pathologically, fibrosis is characterised by the expansion of connective tissue due to...
2.
Leslie J, Macia M, Luli S, Worrell J, Reilly W, Paish H, et al.
Nat Metab
. 2020 Dec;
3(1):118-119.
PMID: 33303984
No abstract available.
3.
Leslie J, Macia M, Luli S, Worrell J, Reilly W, Paish H, et al.
Nat Metab
. 2020 Nov;
2(11):1350-1367.
PMID: 33168981
Fibrosis is a common pathological feature of chronic disease. Deletion of the NF-κB subunit c-Rel limits fibrosis in multiple organs, although the mechanistic nature of this protection is unresolved. Using...
4.
Woodcock H, Eley J, Guillotin D, Plate M, Nanthakumar C, Martufi M, et al.
Nat Commun
. 2020 Sep;
11(1):4680.
PMID: 32917879
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Good R, Eley J, Gower E, Butt G, Blanchard A, Fisher A, et al.
BMC Biomed Eng
. 2020 Sep;
1:14.
PMID: 32903343
Background: Excessive extracellular matrix (ECM) deposition is a hallmark feature in fibrosis and tissue remodelling diseases. Typically, mesenchymal cells will produce collagens under standard 2D cell culture conditions, however these...
6.
Ronnow S, Dabbagh R, Genovese F, Nanthakumar C, Barrett V, Good R, et al.
Respir Res
. 2020 May;
21(1):108.
PMID: 32381012
Background: Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with challenging management. To find novel effective therapies, better preclinical models are needed for the screening of anti-fibrotic compounds. Activated...
7.
Organ L, Duggan A, Oballa E, Taggart S, Simpson J, Kangombe A, et al.
Respir Res
. 2019 Jul;
20(1):148.
PMID: 31299951
Idiopathic pulmonary fibrosis (IPF) is characterised by excessive extracellular matrix (ECM) deposition and remodelling. Measuring this activity provides an opportunity to develop tools capable of identifying individuals at-risk of progression....
8.
Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts
Martufi M, Good R, Rapiteanu R, Schmidt T, Patili E, Tvermosegaard K, et al.
CRISPR J
. 2019 Apr;
2:31-40.
PMID: 31021235
Genome editing is a tool that has many applications, including the validation of potential drug targets. However, performing genome editing in low-passage primary human cells with the greatest physiological relevance...
9.
Woodcock H, Eley J, Guillotin D, Plate M, Nanthakumar C, Martufi M, et al.
Nat Commun
. 2019 Jan;
10(1):6.
PMID: 30602778
Myofibroblasts are the key effector cells responsible for excessive extracellular matrix deposition in multiple fibrotic conditions, including idiopathic pulmonary fibrosis (IPF). The PI3K/Akt/mTOR axis has been implicated in fibrosis, with...
10.
Gisli Jenkins R, Moore B, Chambers R, Eickelberg O, Konigshoff M, Kolb M, et al.
Am J Respir Cell Mol Biol
. 2017 May;
56(5):667-679.
PMID: 28459387
Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges...